drugset / Trial / NCT00755976
Sulindac and Epirubicin in Treating Patients With Metastatic Malignant Melanoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
RATIONALE: Sulindac may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as epirubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving sulindac together with epirubicin may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving sulindac together with epirubicin works in treating patients with metastatic malignant melanoma.
Timeline
- Start
- 2007-08
- Primary completion
- 2010-05
- Completion
- 2010-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Epirubicin | Small molecule | 75 mg/m2 | Intravenous |
| Subject | Sulindac | Small molecule | 600 mg | Oral |